Baxter International Inc (NYSE:BAX) declared a quarterly dividend on Tuesday, November 19th, RTT News reports. Shareholders of record on Friday, December 6th will be given a dividend of 0.22 per share by the medical instruments supplier on Thursday, January 2nd. This represents a $0.88 dividend on an annualized basis and a yield of 1.08%. The ex-dividend date of this dividend is Thursday, December 5th.
Shares of Baxter International stock opened at $81.86 on Tuesday. Baxter International has a 12-month low of $61.40 and a 12-month high of $89.93. The stock has a market capitalization of $41.85 billion, a P/E ratio of 26.84, a price-to-earnings-growth ratio of 2.11 and a beta of 0.98. The company has a 50-day simple moving average of $81.66 and a 200 day simple moving average of $82.72. The company has a quick ratio of 2.10, a current ratio of 2.78 and a debt-to-equity ratio of 0.72.
In other Baxter International news, SVP Jacqueline Kunzler sold 5,934 shares of the business’s stock in a transaction on Thursday, September 5th. The shares were sold at an average price of $88.12, for a total value of $522,904.08. Following the completion of the sale, the senior vice president now directly owns 3,089 shares of the company’s stock, valued at $272,202.68. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Andrew Frye sold 3,332 shares of the company’s stock in a transaction dated Monday, October 14th. The shares were sold at an average price of $88.00, for a total transaction of $293,216.00. Following the sale, the senior vice president now owns 16,391 shares of the company’s stock, valued at $1,442,408. The disclosure for this sale can be found here. Insiders have sold 9,446 shares of company stock worth $831,917 over the last quarter. Company insiders own 0.70% of the company’s stock.
Several equities research analysts have issued reports on BAX shares. ValuEngine lowered shares of Baxter International from a “buy” rating to a “hold” rating in a research report on Wednesday, October 2nd. Piper Jaffray Companies restated a “buy” rating on shares of Baxter International in a research report on Tuesday, September 10th. JPMorgan Chase & Co. set a $94.00 target price on shares of Baxter International and gave the stock a “buy” rating in a research report on Tuesday, October 8th. Finally, Deutsche Bank initiated coverage on Baxter International in a research note on Monday, October 21st. They issued a “buy” rating and a $109.00 target price on the stock. Five analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $89.77.
About Baxter International
Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products. The company operates through North and South America; Europe, Middle East and Africa; and Asia-Pacific segments. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; renal replacement therapies and other organ support therapies focused in the intensive care unit; sterile intravenous (IV) solutions, IV therapies, infusion pumps, administration sets, and drug reconstitution devices; and parenteral nutrition therapies.
Featured Story: How are Outstanding Shares Different from Authorized Shares?
Receive News & Ratings for Baxter International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International and related companies with MarketBeat.com's FREE daily email newsletter.